The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This study was a single-arm, multicenter, phase Π clinical study. Patients admitted to the
enrollment unit center with a confirmed diagnosis of TDNSAA/VSAA/SAA, treated with IST
(p/r-ATG+CSA) in combination with TPO-RA (including eltrombopta or hydtrombopta) for at least
3 months with no hematologic response at 6-month follow-up, and who were not suitable or
unwilling to undergo hematopoietic stem cell transplantation (HSCT), were to another novel
TPO-RA avatrombopta, 40-60 mg (weight <80 kg), in addition to maintaining the original
immunosuppressive therapy ( CSA or equivalent immune potency drugs), switch to another new
TPO-RA avatropa 40-60 mg (40 mg daily for weight <80 kg; 60 mg daily for weight >80 kg)
orally once daily for at least 3 months and follow up for 3 months to determine the
hematologic response and to assess the safety of the drug
Phase:
N/A
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Collaborators:
First Affiliated Hospital of Harbin Medical University Peking University People's Hospital Second Hospital of Shanxi Medical University The First Hospital of Hebei Medical University Xiyuan Hospital of China Academy of Chinese Medical Sciences